• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重性抑郁障碍与双相障碍 II 之间快感缺失的差异。

Anhedonia difference between major depressive disorder and bipolar disorder II.

机构信息

Department of Geriatric Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, People's Republic of China.

Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China.

出版信息

BMC Psychiatry. 2021 Oct 27;21(1):531. doi: 10.1186/s12888-021-03548-w.

DOI:10.1186/s12888-021-03548-w
PMID:34706699
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8555067/
Abstract

OBJECTIVE

This study aims to explore the difference in anhedonia between Major Depressive Disorder (MDD) and Bipolar Disorder II (BD-II), and attempt to distinguish the two diseases through Snaith-Hamilton Pleasure Scale (SHAPS).

METHODS

A total of 164 drug-free depressive patients (98 MDD patients, 66 BD-II patients) completed the investigation. 17-item Hamilton Depression Scale (HAMD-17) and Hamilton Anxiety Scale (HAMA) and SHAPS were assessed in all participants.

RESULTS

Our results showed that BD-II patients had higher SHAPS scores than MDD patients. The stepwise logistic regression analysis further revealed that SHAPS score, drinking habit, and extroversion as influencing factors for the identification of BD-II. The ROC curve analysis indicated that SHAPS could differentiate BD-II from MDD patients (AUC = 0.655, P = 0.001, 95% CI = 0.568 to 0.742), with the best screening cutoff at 26, and the corresponding sensitivity and specificity was 0.788 and 0.520, respectively.

CONCLUSION

Our results suggest that BD-II patients had more severe anhedonia compared to MDD patients, and the difference in anhedonia may help clinicians preliminary identify BD patients from MDD patients. The preliminary findings are worthly of further exploration.

摘要

目的

本研究旨在探讨重性抑郁障碍(MDD)与双相情感障碍 II 型(BD-II)之间快感缺失的差异,并尝试通过 Snaith-Hamilton 快感量表(SHAPS)来区分这两种疾病。

方法

共纳入 164 名未用药的抑郁患者(98 名 MDD 患者,66 名 BD-II 患者)参与本研究。所有参与者均完成了 17 项汉密尔顿抑郁量表(HAMD-17)、汉密尔顿焦虑量表(HAMA)和 SHAPS 的评估。

结果

我们的研究结果表明,BD-II 患者的 SHAPS 评分高于 MDD 患者。逐步逻辑回归分析进一步表明,SHAPS 评分、饮酒习惯和外向性是区分 BD-II 的影响因素。ROC 曲线分析表明,SHAPS 可以区分 BD-II 与 MDD 患者(AUC=0.655,P=0.001,95%CI=0.568 至 0.742),最佳筛查截断值为 26,对应的灵敏度和特异性分别为 0.788 和 0.520。

结论

我们的研究结果表明,BD-II 患者的快感缺失比 MDD 患者更严重,快感缺失的差异可能有助于临床医生初步从 MDD 患者中识别 BD 患者。初步发现值得进一步探索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd93/8555067/96abcae437bc/12888_2021_3548_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd93/8555067/96abcae437bc/12888_2021_3548_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bd93/8555067/96abcae437bc/12888_2021_3548_Fig1_HTML.jpg

相似文献

1
Anhedonia difference between major depressive disorder and bipolar disorder II.重性抑郁障碍与双相障碍 II 之间快感缺失的差异。
BMC Psychiatry. 2021 Oct 27;21(1):531. doi: 10.1186/s12888-021-03548-w.
2
Evaluation of anhedonia with the Snaith-Hamilton Pleasure Scale (SHAPS) in adult outpatients with major depressive disorder.使用斯奈斯 - 汉密尔顿愉悦量表(SHAPS)对成年重度抑郁症门诊患者的快感缺失进行评估。
J Psychiatr Res. 2015 Jun;65:124-30. doi: 10.1016/j.jpsychires.2015.03.010. Epub 2015 Mar 21.
3
Psychometric evaluation of the Snaith-Hamilton pleasure scale in adult outpatients with major depressive disorder.《Snaith-Hamilton 愉悦量表在成年门诊重性抑郁障碍患者中的心理测量评估》
Int Clin Psychopharmacol. 2010 Nov;25(6):328-33. doi: 10.1097/YIC.0b013e32833eb5ee.
4
High efficiency of left superior frontal gyrus and the symptom features of major depressive disorder.左额上回效率与重性抑郁障碍的症状特征。
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Mar 28;47(3):289-300. doi: 10.11817/j.issn.1672-7347.2022.210743.
5
Reliability and Validity of the Snaith-Hamilton Pleasure Scale Clinician Administered Turkish Form.斯奈思-汉密尔顿快感量表临床医师管理土耳其语形式的信度和效度。
Turk Psikiyatri Derg. 2022 Fall;33(3):187-195. doi: 10.5080/u25844.
6
Factor Structure and Measurement Invariance of the Chinese version of the Snaith-Hamilton Pleasure Scale (SHAPS) in Non-clinical and Clinical populations.中文版本的 Snaith-Hamilton 愉悦量表(SHAPS)在非临床和临床人群中的因子结构和测量不变性。
J Affect Disord. 2021 Feb 15;281:759-766. doi: 10.1016/j.jad.2020.11.068. Epub 2020 Nov 13.
7
Assessment of Anhedonia in Adults With and Without Mental Illness: A Systematic Review and Meta-analysis.成人有无精神疾病的快感缺失评估:系统评价和荟萃分析。
JAMA Netw Open. 2020 Aug 3;3(8):e2013233. doi: 10.1001/jamanetworkopen.2020.13233.
8
Assessment of Snaith-Hamilton Pleasure Scale (SHAPS): the dimension of anhedonia in Italian healthy sample.评估斯内思-汉密尔顿快感量表(SHAPS):意大利健康样本中快感缺失的维度。
Neurol Sci. 2018 Apr;39(4):657-661. doi: 10.1007/s10072-018-3260-2. Epub 2018 Jan 30.
9
Inflammatory cytokines, complement factor H and anhedonia in drug-naïve major depressive disorder.炎症细胞因子、补体因子 H 和药物初治的重性抑郁障碍中的快感缺失。
Brain Behav Immun. 2021 Jul;95:238-244. doi: 10.1016/j.bbi.2021.03.022. Epub 2021 Mar 29.
10
[Translation into Spanish and validation of the Snaith-Hamilton Pleasure Scale (SHAPS) for anhedonia].[《无快感的斯奈斯 - 汉密尔顿愉悦量表(SHAPS)的西班牙语翻译及验证》]
Actas Esp Psiquiatr. 2013 Jul-Aug;41(4):227-31. Epub 2013 Jul 1.

引用本文的文献

1
Association of subclinical hypothyroidism with metabolic syndrome and its components among outpatients with first-episode drug-naïve major depressive disorder: a large-scale cross-sectional study.亚临床甲状腺功能减退与首发未经药物治疗的单相重性抑郁障碍门诊患者代谢综合征及其组份的相关性:一项大规模的横断面研究。
Eur Arch Psychiatry Clin Neurosci. 2024 Apr;274(3):573-582. doi: 10.1007/s00406-023-01588-9. Epub 2023 Mar 24.

本文引用的文献

1
Inflammatory cytokines, complement factor H and anhedonia in drug-naïve major depressive disorder.炎症细胞因子、补体因子 H 和药物初治的重性抑郁障碍中的快感缺失。
Brain Behav Immun. 2021 Jul;95:238-244. doi: 10.1016/j.bbi.2021.03.022. Epub 2021 Mar 29.
2
Economic Burden of Treatment-Resistant Depression in Privately Insured U.S. Patients with Physical Conditions.有躯体疾病的美国私人保险患者中,治疗抵抗性抑郁症的经济负担。
J Manag Care Spec Pharm. 2020 Aug;26(8):996-1007. doi: 10.18553/jmcp.2020.20017. Epub 2020 Jun 19.
3
Characterizing anhedonia: A systematic review of neuroimaging across the subtypes of reward processing deficits in depression.
描述快感缺失:抑郁症中不同奖赏加工缺陷亚型的神经影像学系统综述。
Cogn Affect Behav Neurosci. 2020 Aug;20(4):816-841. doi: 10.3758/s13415-020-00804-6.
4
Patient health questionnaire-15 (PHQ-15) to distinguish bipolar II disorder from major depressive disorder.患者健康问卷-15(PHQ-15)区分双相 II 障碍与重性抑郁障碍。
Psychiatry Res. 2020 Aug;290:113026. doi: 10.1016/j.psychres.2020.113026. Epub 2020 May 17.
5
Increased ratio of mature BDNF to precursor-BDNF in patients with major depressive disorder with severe anhedonia.伴有严重快感缺乏的重度抑郁症患者中成熟脑源性神经营养因子与前体脑源性神经营养因子的比例增加。
J Psychiatr Res. 2020 Jul;126:92-97. doi: 10.1016/j.jpsychires.2020.05.010. Epub 2020 May 12.
6
Emotional Contexts Modulate Anticipatory Late Positive Component and Reward Feedback Negativity in Adolescents With Major Depressive Disorder.情绪背景调节重度抑郁症青少年的预期晚期正波成分和奖励反馈负波
Front Psychiatry. 2020 Apr 29;11:358. doi: 10.3389/fpsyt.2020.00358. eCollection 2020.
7
Efficacy of adjunctive infliximab vs. placebo in the treatment of anhedonia in bipolar I/II depression.辅助使用英夫利昔单抗与安慰剂治疗双相 I/II 型抑郁症快感缺失的疗效比较。
Brain Behav Immun. 2020 Aug;88:631-639. doi: 10.1016/j.bbi.2020.04.063. Epub 2020 May 4.
8
Abnormal functional connectivity as neural biological substrate of trait and state characteristics in major depressive disorder.异常的功能连接作为重性抑郁障碍特质和状态特征的神经生物学基础。
Prog Neuropsychopharmacol Biol Psychiatry. 2020 Aug 30;102:109949. doi: 10.1016/j.pnpbp.2020.109949. Epub 2020 Apr 23.
9
Gut Microbial Signatures Can Discriminate Unipolar from Bipolar Depression.肠道微生物特征可区分单相抑郁和双相抑郁。
Adv Sci (Weinh). 2020 Feb 5;7(7):1902862. doi: 10.1002/advs.201902862. eCollection 2020 Apr.
10
Discriminating bipolar depression from major depressive disorder with polygenic risk scores.利用多基因风险评分鉴别双相情感障碍抑郁发作与重度抑郁症
Psychol Med. 2021 Jul;51(9):1451-1458. doi: 10.1017/S003329172000015X. Epub 2020 Feb 17.